Sample size: 80; 39 historical control from Lowrie et al (2013) treated with subcutaneous (SC) CA, 41 prospectively recruited to receive continuous rate infusion (CRI) CA.
Intervention details:
 The CRI CA dogs received a neurologic examination,
PICO question
In treatment of canine patients with meningoencephalitis of unknown origin (MUO), is combination therapy of cytosine arabinoside (CA) with prednisolone more effective than prednisolone as a sole therapy at increasing survival time?
Clinical bottom line
Based on current available evidence, cytosine arabinoside with prednisolone has greater median survival time than prednisolone as a sole therapy in dogs with meningoencephalitis of unknown origin. The evidence to support this is very weak, as there are currently a low number of published papers with a relatively small number of cases reported in these studies evaluating cytosine arabinoside with prednisolone or prednisolone as a sole therapy for treatment of meningoencephalitis of unknown origin. complete blood count (CBC), serum biochemistry profile, serum antibody titres to Neospora caninum and Toxoplasma gondii, brain MRI, CSF analysis. The SC CA control group received the same with the exception to testing for Toxoplasma gondi.  Both groups were treated with a standard protocol for immunosuppressive doses of oral prednisolone (1mg/kg twice daily (BID) with tapering doses after 4 weeks). This was reduced to 0.5mg/kg BID for 6 weeks, then 0.25mg/kg BID for 6 weeks, then 0.25mg/kg once daily for 6 weeks, then 0.25mg/kg every 48hours for 6 weeks followed by 0.25mg/kg every 72 hours for 6 weeks.  Dogs in the historical control group (Lowrie et al 2013) received subcutaneous CA at 50mg/m 2 every 12 hours for 2 days repeated every 3 weeks before increasing the treatment intervals by a week every 4 treatment cycles.  Dogs prospectively recruited received CA CRI at 100mg/m 2 over 24 hours. They then received 50mg/m2 SC CA every 12 hours for 2 days every 3 weeks for 3 cycles before increasing the treatment by a week every 4 treatment cycles.  Repeat MRI and CSF analysis at 3 months following the start of treatment for the prospectively recruited CRI group and historical SC group.
Study design: Prospective cohort study with historical control group
Outcome studied: The effect of a CA CRI on mortality in dogs with MUO and compare CA CRI to CA SC.
Objective:  Mortality at 3 months (dogs that died or were euthanised were recorded and survival was compared as a binary value with a group of historical control dogs).  Occurrence of MRI and CSF abnormalities at follow-up.
Main findings: (relevant to PICO question):
 Mortality of 4/41 (10%) in CA CRI group (compared with 22/39 (56%) with in CA SC group) at 3 months. Log rank analysis of the Kaplan-Meier survival curves represented a significantly better survival with CA CRI. All dogs alive at 3 months in both groups were alive at 12 months.  34/37 surviving dogs in the CRI group had a normal MRI scan at 3 months compared with 7/17 surviving dogs in the SC group (statistically significant difference between the groups).  CSF was normal in a significantly higher proportion of dogs in the CA CRI group (36/37) compared to the SC group (10/17).
Limitations:
 Historical control data gathered at a different time period from a different study. 
Sample size: 39
Intervention details:  All dogs received a neurologic examination, complete blood count, serum biochemistry profile, serum antibody titres to Neospora caninum, brain MRI, CSF analysis.  All dogs were treated with a standard protocol initiated with immunosuppressive doses of oral prednisolone; 1mg/kg twice daily (BID) with tapering doses after 4 weeks to 0.5mg/kg BID PO for 6 weeks, followed by 0.25mg/kg BID for 6 weeks, followed by 0.25mg/kg once daily (SID) for 6 weeks, followed by 0.25mg/kg every 48 hours for 6 weeks, followed by 0.25mg/kg every 72 hours for 6 weeks.  Dogs received subcutaneous CA at 50mg/m 2 every 12 hours for 2 days repeated every 3 weeks for 4 cycles, before decreasing the frequency at the same dose to every 4 weeks for 4 cycles, then every 5 weeks for 4 cycles followed by every 6 weeks for 4 cycles.  Repeat MRI and CSF analysis at 3 months following the start of treatment. If abnormal the treatment regime was altered accordingly to prolong treatment. If a relapse occurred the protocol was restarted. 
Limitations:
 No histopathological data to confirm type of meningioencephalitis.  Dogs with optic form of GME were excluded from the study.
Flegel (2011)
Population: Dogs presenting to Department of Small Animal medicine, University of Leipzig or Department of Clinical Neurology, University of Bern, between June 2000 and September 2008 with presumptive or diagnosed granulomatous meningoencephalitis (GME) or necrotizing (NME)/necrotizing leukocephalitis (NLE).
Sample size: 43 dogs; 25 with GME and 18 with NME/NLE split into 1 of 2 treatment groups based on treatment received. Dogs with GME in group 1 (n = 14) treated with a combination of lomustine and prednisolone and group 2 (n = 11) treated with prednisolone alone. Dogs with NME/NLE in group 3 treated with a combination of lomustine (n = 10) and prednisolone and group 4 treated with prednisolone alone (n = 8).
Intervention details:
 All dogs received a neurologic examination, complete blood count, serum biochemistry profile, serum antibody titres to Neospora caninum, Toxoplasma gondii and Erlichia canis, brain MRI, CSF analysis and antibodies against canine distemper in 19/25 dogs with GME. Some dogs received a needle brain biopsy for diagnosis of GME/NLE/NME otherwise it was considered a presumptive diagnosis of meningoencephalitis.  All dogs were initially treated with 0.17-2.5mg/kg oral prednisolone twice daily immediately after diagnostic tests had been completed.  14 dogs with presumed or diagnosed GME and ten dogs with presumed or diagnosed NME/NLE were given oral lomustine (44 to 88mg/m 2 every 6 weeks) and prednisolone. Lomustine dose was reduced by 25% if leukopenia developed. Prednisolone dose was assessed every 6 weeks and reductions made in decrements of 20% (frequency of administration remained constant at twice daily) in the absence of neurological deficits, less than one seizure per month and clinicopathologic results analysis (CBC).  11 dogs with presumed or diagnosed GME and eight dogs with presumed or diagnosed NME/NLE were treated with prednisolone as a sole therapy. Dose reductions were attempted every 6 to 8 weeks (in decrements of 20% while maintaining dose frequency) in accordance with the absence of neurological deficits, under one seizure a month, assessed through a neurological examination or communication with the owner. In some instances owners made their own decision in reducing dosages.
Study design: Retrospective cohort study
Outcome studied: Comparing oral lomustine and prednisolone to prednisolone alone as for treatment of MUO.
Objective measured:  Survival
Main findings: (relevant to PICO question):
 Diagnosis was confirmed in 8/25 GME dogs and 5/18 NME/NLE dogs. 2 dogs with GME and 2 dogs with NME/NLE via histologic examination of brain biopsy specimens and 6 GME dogs and 3 NME/NLE dogs at necropsy.  9/13 dogs that died in group 1 had documented cause of death; 3 due to recurrence of neurological signs and 6 due to non-neurologic conditions (renal failure, cardiac failure, hemorrhagic gastroenteritis, septic shock and suspected liver failure).  5/8 dogs that died in group 2 had documented causes of death; 4 due to lack of improvement or relapse of neurologic signs and 1 due to chronic renal failure.  All dogs in group 3 (8/8) had documented cause of death; 3 due to recurrence of neurologic signs and 5 due to other medical conditions (such as pleural effusion, cardiac failure, septic shock, gastrointestinal hemorrhage).  5/8 dogs reason for euthanasia was documented in group 4, all due to lack of improvement or relapse of neurologic signs.  Median survival was 323 days (39-542 days) in dogs treated with prednisolone as a sole therapy with GME, and 457 days (107-709 days) in dogs treated with lomustine and prednisolone. No significant difference was found between these groups (1 and 2).  Median survival was 91 days (7-494 days) in dogs treated with prednisolone as a sole therapy with NME/NLE, and 329 days (98-628 days) in dogs treated with prednisolone and lomustine. No significant difference was found between these groups (3 and 4).  Reduction in median prednisolone dose per day within the first 12 months of treatment was seen in in dogs with GME treated with lomustine and prednisolone from 2.1 to 0.2mg/kg/day compared to 1.4 to 0.6mg/kg/day for dogs treated with prednisolone alone.  Reduction in median prednisolone dose per day within the first 12 months of treatment was seen in in dogs with NME/NLE treated with lomustine and prednisolone from 1.9 to 0mg/kg/day compared to 2.1 to 1.0mg/kg/day for dogs treated with prednisolone alone.  In 4 dogs with GME and 4 dogs with NME/NLE prednsisolone administration was able to be discontinued. In 3 of these GME affected dogs lomustine was also discontinued.
Limitations:
 No standard treatment protocol, differing dose ranges (including owners making decisions on tapering doses).  Small number of cases, no power calculation performed.  Diagnosis in (number) of dogs was carried out at post mortem. Sample size: 19 dogs split into 2 groups; group 1 treated with prednisolone in combination with vincristine and cyclophosphamide (n=10) and group 2 treated with prednisolone with cytosine arabinoside (n=9). Group 2 had 10 cases but one was retrospectively excluded for failing to meet the inclusion criteria. . No further treatment of CA was given.  In groups 1 and 2, oral prednisolone was reduced from 40mg/m 2 every 24 hours doe 7 days to 20mg/m 2 every 48 hours for 7 weeks, then the same regimen given in alternate weeks. The dose of prednisolone was tapered to suit individual requirements after 6 months and stopped if possible.  Patients were followed for survival analysis and those alive at the time of writing were censored from survival estimate using an intention-to-treat analysis. The proportion of animal surviving 1 and 12 months was calculated excluding the censored cases in Kaplan-Meier analysis.
Smith (2009)
Population
Study design: Randomised control trial (double blinded)
Outcome studied: Comparing COP lymphoma protocol to prednisolone with CA treatment for MUO Objective:  Survival analysis; Kaplin-Meier Analysis.  Treatment failure analysis.  Drug-related complications.
Main findings: (relevant to PICO question):
 For survival analysis three dogs were censored from group 2 including two that were euthanised for non-neurological disease (lymphoma and pneumonia) and one whose treatment was altered after a relapse (surviving for over a year receiving only prednisolone). Two were censored from group 1, both of whose treatment were stopped. 3 dogs were alive at time of writing in group 2 and 4 dogs in group 1, which were censored.  Median survival was estimated at 1,063 days in dogs treated with prednisolone and CA (group 2 p a g e | 9 of 15 group 1.  Proportion of animals surviving 1 and 12 months was calculated (excluding the censored cases) in Kaplan-Meier analysis leaving 7 animals in group 2 and 8 animals in group 1. 5/7 animals were alive at both 1 and 12 months in group 2, 5/8 animals were alive at 1 month and 4/8 were alive at 12 months for group 1.  One animal in group 2 which worsened at day 40 but ultimately survived for 376 days (Kaplin-Meier plot of timeto-treatment failure with a median value of 1063 days in group 2 (102-2023)).
Limitations:
 Small population size. One case excluded from CA and prednisolone group due to CSF sample containing 90% neutrophils.  Lack of follow-up and survival times.  Two cases of possible infectious disease not ruled out due to severity of cases and need to start treatment.  Confusing results -difficult to interpret survival analysis. In group 2, the removal of censored cases is unclear for the specific test and analysis (3 cases censored due to being alive and 3 due to euthanasia or treatment change).
Menaut (2008)
Population: Dogs presenting to the National Veterinary School of Toulouse between September 2003 and January 2005 with presumptive or diagnosed MUO.
Sample size: 11
Intervention details:  Dogs were selected based on treatment with a combination of steroids and CA.  Covered some of the six criteria for MUO presumptive diagnosis including focal or multifocal central nervous system (CNS) signs, negative PCR and CSF analysis for infectious disease (distemper, neospora, toxoplasma, erlichiosis), CSF protein and white blood cell (WBC) analysis, CT signs consistent with MUO, ophthalmoscopy signs of optic neuritis, histopathological diagnosis.  All dogs were treated with oral immunosuppressive prednisolone (1-2 mg/kg twice daily tapered over 3 months) and subcutaneous CA (50mg/m 2 every 12 hours for 48 hours repeated every 3 weeks). At week 28 the CA treatment interval was tried to be lengthened by one week every 4 weeks. Prednisolone dose was tapered from 2mg/kg twice daily (BID) for 1 week, to 1.5mg/kg BID for 1 week, then 1mg/kg BID for 1 week, then 0.75mg/kg BID for 1 week, then 0.5mg/kg BID for 2 weeks, then 1mg/kg every other day for 3 weeks, then 1mg/kg every third day for 2 weeks then to be stopped if possible.  Intravenous steroid therapy was initiated for 2-3 days in nine of the dogs without reason given for this.  Where possible a CBC was performed at 7 days after each CA treatment.
Veterinary Evidence

Study design: Retrospective case series
Outcome studied: Response to prednisolone and subcutaneous CA treatment in dogs with MUO.
Subjective  Quality of life was judged by the owner and referring veterinarian. Objective:
 Survival time and cumulative probability of survival at 2 years.
Main findings: (relevant to PICO question):
 At the end of the study seven dogs were alive and four had died (one due to drowning, one due to neurologically associated pancreatitis and hypoglycaemia, one dog euthanised at the first relapse and the other dog euthanised at the fourth relapse).  Median survival 384 days, range 78-603.  Median survival time could not be calculated using KaplanMeier analysis as fewer than half the animals had died. The cumulative probability of survival at 2 years was 58.4%.  Initial response to treatment was judged as excellent with total remission of clinical signs and excellent quality of life in five dogs, good with partial remission and good quality of life in five dogs, and poor with poor control of disease in one dog.  Seven dogs experienced relapses. In three of these relapse occurred due to steroid dose reduction. In one of these dogs another relapse occurred due to a delay in CA treatment due to pyometra. One dog had a relapse with discontinuation of its CA treatment by the owners. In three cases the cause of relapse was unknown. One of the dogs who relapsed after 3 months of treatment was euthanised as the owner would not accept further treatment.
Limitations:
 No standard treatment protocol, tapering dose altered by clinicians depending on each dog's response to treatment, side effects, number of relapses and owner compliance.  Varied CA treatment cycles ranging from 4 to 37 treatments.  Only one dog had clinical confirmation of GME.  Only included cases that survived long enough for CA therapy.  Small number of cases collected for the study. 
Sample size: 10
Intervention details:  Dogs were selected based on treatment with a combination of steroids and CA.  Covered some of the six criteria for MUO presumptive diagnosis including focal or multifocal CNS signs, negative PCR and CSF analysis for infectious disease (five dogs), CSF protein and WBC analysis (CSF mononuclear pleocytosis), CT signs consistent with MUO (nine dogs), ophthalmoscopy signs of optic neuritis, histopathological diagnosis.  A minimum database of CBC, serum biochemistry profie, blood serology for infectious encephalopathies (Anaplasma phagocytophilum, Ehrlichia canis, Toxoplasma gondii, Neospora canis, Cryptococcus (in nine dogs). Antinuclear antibody titres were performed in two dogs with immunemediated disease.  Each dog was treated with immunosuppressive doses of corticosteroids. Six dogs received 0.1-1.0mg/kg oral dexamethasone sodium phosphate or 10-30mg/kg methylp sodium succinate. All dogs received 1-2mg/kg prednisolone twice daily at the time of diagnosis.  Approximately 15mg/kg Clindamycin was given twice daily and 5mg/kg Doxycycline twice daily were given initially but discontinued after negative infectious disease titres (5-7 days after diagnosis).  CA treatment was initiated at variable intervals (from 0 to 60 days later) at 50mg/m 2 subcutaneously twice a day for two consecutive days. The CA protocol was repeated every 3 weeks for 4 months (where the treatment interval was then lengthened by a week every 4 months with a maximum final interval of every 8 weeks).  One dog had repeat CT at 7 months and two dogs (including the dog with repeat CT) had repeat CSF analysis. 
Appraisal, application and reflection
All cases of MUO were assumed through neurological examination and included some or all of advanced imaging techniques, CSF analysis or diagnosed with antemortem brain biopsy or postmortem histopathology. It should be taken into account that each of these studies is focused on populations of animals attending referral centers rather than general practice. None of the studies directly compared the treatment of MUO with either a combination therapy of CA with prednisolone to prednisolone as a sole therapy. Only one study evaluated the use of prednisolone as a sole therapy for treatment of MUO, but was used as a comparison for a different chemotherapeutic agent and involved a range of different treatment doses, including at the initiation of therapy. Three out of six studies were performed by a retrospective search of cases. This may lead to selection bias and may not give accurate representation evaluating treatment of MUO as some cases may die shortly after admission or prior to commencing treatment (e.g. Lowrie et al., 2016) . Retrospective case series sit low on the hierarchy of evidence and despite some of the studies having greater strength (randomised controlled trial > cohort study > case series), it is difficult to draw definitive conclusions from the available literature.
A treatment protocol was implemented in three of the studies, however the prednisolone dose or frequency in these, as well as the studies without a treatment protocol, would be altered to the individual patients based upon relapses and clinical signs. 
Methodology Section Search Strategy
Databases searched and dates covered:
The search was applied to CAB abstracts and Medline databases from 1946 to January 2017. Total relevant papers when duplicates removed 6
